NCT05675579进行中（未招募）2 期
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 27
- 试验地点
- 2
- 主要终点
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
研究概览
简要总结
To learn if sacituzumab govitecan and pembrolizumab, when given before surgery, can help to control early-stage triple negative breast cancer that has not responded well to other treatments.
详细描述
Primary Objective:
• To determine the efficacy of sacituzumab govitecan and pembrolizumab combination treatment on pathological complete response (pCR)/residual cancer burden (RCB)-1 in the patients with early-stage TNBC who showed a resistance to the combination of immunochemotherapy.
Secondary Objectives:
- To determine the safety of the proposed combination treatment.
- To determine the objective overall response rate (ORR) of the proposed treatment.
- To determine the distant-recurrence-free survival (DRFS).
- To determine the 3-year event-free survival (EFS) rate.
- To determine the 3-year overall survival (OS) rate.
Exploratory Objective:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female or male patients 18 years of age or older.
- •Histologically or cytologically confirmed breast cancer
- •T1c N1-2 or T2-4 N0-2 early-stage disease
- •ER/PR negative (ER/PR <1%) or ER/PR low positive (1%≤ER/PR≤10%), and HER2 negative as per institutional and ASCO-CAP guidelines)
- •Initiated the NAC with the first regimen of KN-522 regimen (i.e., pembrolizumab 200 mg Q3W, given with 4 cycles of paclitaxel + carboplatin).
- •ECOG performance score of 0 or
- •The volumetric change of primary tumor = 0% or increase in volumetric size by US or MRI after completing the first part of the KN-522 regimen.
- •Negative serum pregnancy test within 72 hours of receiving the first dose of the study medication for women of childbearing potential as per institutional guidelines. Postmenopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo pregnancy tests.
- •Agreed with undergoing the image-guided core needle biopsy after completing the first part of neoadjuvant treatment regimen.
- •Subjects of childbearing potential should be willing to use effective birth control methods or be surgically sterile or abstain from heterosexual activity for the course of the study through at least 4 months after the last dose of the study drug. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year. Effective methods of birth control include:
- •Use hormonal birth control methods: pills, shots/injections, implants (placed under the skin by a health care provider), or patches (placed on the skin).
- •Intrauterine devices (IUDs).
- •Using 2 barrier methods (each partner must use 1 barrier method) with a spermicide. Males must use the male condom (latex or other synthetic material) with spermicide. Females must choose either a Diaphragm with spermicide, cervical cap with spermicide, or a sponge.
- •The patient must have adequate organ function as determined by the following laboratory values:
- •Absolute neutrophil count* ≥ 1,500 /μL
- •Platelets* ≥ 100,000 /μL
- •Hemoglobin* ≥ 9 g/dL
- •Creatinine clearance > 50 ml/min
- •Total bilirubin ≤ 1.5 X ULN
- •Alanine aminotransferase and aspartate aminotransferase < 2.5 X ULN *Hematologic counts above should be without transfusion or growth factor support within 2 weeks of study drug initiation.
排除标准
- •Stage IV disease
- •Any other previous antitumor therapies for the current cancer event.
- •Pregnant or planning to become pregnant during therapy.
- •Gastrointestinal tract disease or defect or previous history of colitis.
- •Has an active autoimmune disease that requires systemic therapy within two years of treatment or a medical condition that requires immunosuppression.
- •Myocardial infarction within 6 months before starting therapy, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication.
- •Has known human immunodeficiency virus (HIV) infection or active hepatitis B or C infection (screen test is not required). Subjects positive for hepatitis C (HCV) antibody are eligible only if the polymerase chain reaction is negative for HCV RNA.
- •Has a cognitive impairment.
- •Any other major comorbidities that can impact receiving immunotherapy or Sacituzumab govitecan.
- •Have live vaccinations within 30 days prior to registration and receive study treatment.
研究组 & 干预措施
Sacituzumab Govitecan and Pembrolizumab
Experimental
Participants will receive drug on Days 1 and 8 of Cycles 1-4, Participants will receive sacituzumab govitecan by vein.
Participants will receive drug on Days 1, 8, and 15 of each cycle, Participants will receive pembrolizumab by vein.
干预措施: Pembrolizumab (Drug)
Sacituzumab Govitecan and Pembrolizumab
Experimental
Participants will receive drug on Days 1 and 8 of Cycles 1-4, Participants will receive sacituzumab govitecan by vein.
Participants will receive drug on Days 1, 8, and 15 of each cycle, Participants will receive pembrolizumab by vein.
干预措施: Sacituzumab Govitecan (Drug)
结局指标
主要结局
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
时间窗: through study completion; an average of 1 year.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk RecurrenceUrothelial CarcinomaMuscle-invasive Bladder CancerNCT06682728University of California, Irvine23
招募中
2 期
Sacituzumab Govitecan In TNBCTriple Negative Breast CancerER-Negative Breast CancerPR-Negative Breast CancerHER2-negative Breast CancerInvasive Breast CancerNCT04230109Massachusetts General Hospital239
招募中
2 期
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder CancerMuscle Invasive Bladder CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8NCT05581589University of Washington18
进行中（未招募）
早期 1 期
Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0GlioblastomaNCT03995706The University of Texas Health Science Center at San Antonio26
招募中
1 期
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard TherapyGastrointestinal CancerNCT06065371Henry Ford Health System20